SIU 2017: The Unmet Need in Locally Advanced RCC Treatment: Game Changers?
Lisbon, Portugal (UroToday.com) In this session, there were three well-respected Urologic Oncologists who were asked to talk about the single most important observation in the recent past. Each chose the area that they felt represented the most exciting discovery.
In this third and final Major Observation, Dr. Mulders discussed S-TRAC,1 the NEJM paper in which sunitinib was assessed in the adjuvant setting for patients with high-risk localized RCC treated with nephrectomy.
SIU 2017: Translational Observations from Mutation Profiling of Muscle Invasive Bladder Cancer
Lisbon, Portugal (UroToday.com) Dr. Lerner provided a very informative update on the current status of translational observations from mutational profiling of muscle invasive bladder cancer (MIBC). There has been significant much-publicized work in this field, and it hoping will lead to prime-time decision-making tools in the near future.
SIU 2017: Can Genetic Analysis in Bladder Cancer Enhance Decision Making
Lisbon, Portugal (UroToday.com) Dr. Black started his presentation by saying that the answer to the title question is “yes (maybe)”. The data is beginning to demonstrate that, but its not quite sufficient enough change in management on a larger scale.
SIU 2017: A Three-Dimensional Bioprinted Bladder Cancer Recurrence Model
Lisbon, Portugal (UroToday.com) Dr. Atala’s group has historically had a great interest in biologically printed organ substitutes, with a focus on bladder substitutes. In bladder cancer, which is one of the most expensive malignancies to treat and monitor, an alternative to test treatments would significantly help reduce the cost burden to the patient and the system.
SIU 2017: Is Re-Implantation Theory True: Post Operative Drainage Tool for Bladder is a Risk Factor of Recurrence in Low Risk Bladder Tumor?
Lisbon, Portugal (UroToday.com) Low-risk pTa TCC is a common presentation of bladder urothelial carcinoma – and while it has low risk of progression, it has a very high rate of recurrence. Likely due to a field defect in the mucosa, there has also been discussion of an implantation theory – disruption of tumor during TURBT leads to free floating TCC cells, which implant in other areas of the bladder, leading to recurrence.
SIU 2017: Accuracy of High B Value Diffusion Weighted MR Imaging in Predicting the Tumor Stage and Grade in Carcinoma of the Urinary Bladder: A Prospective Study on 3 Tesla
Lisbon, Portugal (UroToday.com) TURBT remains the standard of care for diagnosis and staging of bladder cancer, at least in the local setting. While additional modalities may be useful in identification of T3/T4 disease and local extension, TURBT is still the primary diagnostic tool. However, under staging in initial TURBT is well established and the procedure itself can be quite invasive; especially if deep resections for accurate staging are required.
SIU 2017: The Long-Term Impact on NMIBC Recurrence within a Matched-Paired, Index-Control Cohort Setting – NBI–Bipolar Plasma Vaporization Hybrid Approach versus the Standard Diagnostic and Therapeutic Management
Lisbon, Portugal (UroToday.com) In this study, the authors assess whether the combination of narrow band imaging (NBI) with white light cystoscopy (WLC) followed by treatment with biopsy and bipolar plasma vaporization (BPV) was better than WLC, resection and traditional monopolar vaporization (MPV).